213 related articles for article (PubMed ID: 26773812)
1. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
3. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
5. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
6. Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?
Novotná E; Morell A; Büküm N; Hofman J; Danielisová P; Wsól V
Arch Toxicol; 2020 Sep; 94(9):3059-3068. PubMed ID: 32588086
[TBL] [Abstract][Full Text] [Related]
7. In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521-A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics.
Jamrozik M; Piska K; Bucki A; Koczurkiewicz-Adamczyk P; Sapa M; Władyka B; Pękala E; Kołaczkowski M
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175180
[TBL] [Abstract][Full Text] [Related]
8. Inhibition study of rabbit liver cytosolic reductases involved in daunorubicin toxication.
Kaiserová H; Kvasnicková E
J Enzyme Inhib Med Chem; 2005 Oct; 20(5):477-83. PubMed ID: 16335056
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.
Ferguson DC; Cheng Q; Blanco JG
Drug Metab Dispos; 2015 Jul; 43(7):922-7. PubMed ID: 25918240
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.
Büküm N; Novotná E; Morell A; Želazková J; Laštovičková L; Čermáková L; Portillo R; Solich P; Wsól V
Biochem Pharmacol; 2021 Oct; 192():114710. PubMed ID: 34339712
[TBL] [Abstract][Full Text] [Related]
11. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract][Full Text] [Related]
12. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes.
Plebuch M; Soldan M; Hungerer C; Koch L; Maser E
Cancer Lett; 2007 Sep; 255(1):49-56. PubMed ID: 17482758
[TBL] [Abstract][Full Text] [Related]
13. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs.
Mordente A; Silvestrini A; Martorana GE; Tavian D; Meucci E
Drug Metab Dispos; 2015 Nov; 43(11):1691-701. PubMed ID: 26265744
[TBL] [Abstract][Full Text] [Related]
15. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase--Carbonyl reductase 1.
Hintzpeter J; Hornung J; Ebert B; Martin HJ; Maser E
Chem Biol Interact; 2015 Jun; 234():162-8. PubMed ID: 25541467
[TBL] [Abstract][Full Text] [Related]
16. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
[TBL] [Abstract][Full Text] [Related]
17. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
18. Induction of aldo-keto reductases (AKR1C1 and AKR1C3) abolishes the efficacy of daunorubicin chemotherapy for leukemic U937 cells.
Matsunaga T; Yamaguchi A; Morikawa Y; Kezuka C; Takazawa H; Endo S; El-Kabbani O; Tajima K; Ikari A; Hara A
Anticancer Drugs; 2014 Sep; 25(8):868-77. PubMed ID: 24743520
[TBL] [Abstract][Full Text] [Related]
19. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
20. The mechanism for anthracycline-induced inhibition of collagen biosynthesis.
Muszyńska A; Wolczyński S; Pałka J
Eur J Pharmacol; 2001 Jan; 411(1-2):17-25. PubMed ID: 11137854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
